HC Wainwright Issues Positive Outlook for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.47) per share for the quarter, up from their previous estimate of ($0.55). HC Wainwright has a "Buy" rating and a $57.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals' Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.41) EPS and FY2027 earnings at $0.95 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter last year, the company earned ($0.73) EPS. Apellis Pharmaceuticals's revenue for the quarter was up 45.2% compared to the same quarter last year.

APLS has been the topic of several other reports. Royal Bank of Canada lowered their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research note on Monday, March 3rd. Wedbush reduced their price target on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. JPMorgan Chase & Co. lifted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. The Goldman Sachs Group cut their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Finally, Morgan Stanley began coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 price target for the company. Eight research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.53.

Remove Ads

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS traded down $0.28 during mid-day trading on Wednesday, reaching $25.04. 1,520,174 shares of the stock were exchanged, compared to its average volume of 1,926,772. The company has a 50 day simple moving average of $29.08 and a 200-day simple moving average of $31.07. The stock has a market capitalization of $3.11 billion, a P/E ratio of -12.33 and a beta of 0.93. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals has a 1 year low of $23.77 and a 1 year high of $63.07.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares during the period. Wolverine Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth $27,000. True Wealth Design LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth $27,000. Signaturefd LLC boosted its stake in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after acquiring an additional 918 shares in the last quarter. Finally, Capital Performance Advisors LLP bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth $56,000. Institutional investors own 96.29% of the company's stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 2,170 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the transaction, the chief financial officer now owns 88,100 shares of the company's stock, valued at approximately $2,528,470. This represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel David O. Watson sold 5,569 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares of the company's stock, valued at $3,482,123. This represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,934 shares of company stock valued at $1,950,261. Company insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).